Shanghai Pharma to send H-share: "Strive for completion by next June"

In the integration of real medicine, the Chinese and western medicine industry, the Shanghai state-owned pharmaceutical industry's only listed platform 10 months after the suspension of two days of Shanghai Medicine (601607, the former closing price of 20.81 yuan) and a big move, the company will issue H-shares to raise capital to 5 major areas. At yesterday's small media meeting, Shanghai medical director Gegyanqiu said. "We strive to maintain the high efficiency of previous major asset restructurings and strive to complete the H-share listing by June next year."　　"One analyst told the Daily Economic news," The main purpose of Shanghai pharmaceutical issue H-shares is to expand the pharmaceutical business sector, with the Chinese Medicine Holdings (01099, close to HK $30.70) H-Shares listed, Kyushu Pass is about to IPO, Shanghai Medical feel the invisible pressure. An h-share offering of 8 billion yuan, Shanghai pharmaceutical, announced today (September 9) that the company intends to issue publicly listed foreign-invested shares (H-shares) for the first time and listed on the main board of the stock exchange of Hong Kong. The announcement showed that the number of H-shares issued by the company does not exceed 25% of the total share capital issued after the issuance, and that the joint bookkeeping manager does not exceed the 15% share of the shares in the issue of the distribution, pricing no less than the share price of the H-shares issued by the Board of Directors of the That is no less than 17.57 yuan, an equivalent of HK $20.　　It is expected that the amount of funds raised is not less than 8 billion yuan, the company will convene a provisional general meeting on September 27 to consider issues such as H shares. It is noteworthy that in yesterday's board of directors, the company's chief of staff also appeared a turnover. Due to the company's work division adjustment, Gegyanqiu resigned as secretary of the board, employing Han Min as the company's board secretary. Data show that Han Min was born in 1977 and studied in the UK and received a master's degree in finance and investment from the University of Nottingham Business School. He has served as deputy general manager of investment Banking Department of China International Finance Limited, director of business and business affairs of Hongkong and Shanghai Banking Corporation Limited, and manager of CCB Shanghai Branch Risk Control Department.　　The background of Han Min's position in Hong Kong, or the key factor in his appointment, compared with the original Gegyanqiu.　　Raising capital to five major areas according to the Shanghai Medical Bulletin, the issuance of the H-share shares will be invested in five areas. First, domestic and foreign pharmaceutical industry mergers and acquisitions. Among them, the acquisition of pharmaceutical group holding antibiotic business assets, in order to achieve the existing medical industry business integration, the formation of a series of market-impact brands and products to enhance the profitability of the company. In addition, the company will actively seek other domestic and foreign mergers and acquisitions of strategic significance, and strive to achieve low-cost, efficient extension of the expansion of the second is the pharmaceutical Business network construction and mergers and acquisitions. The company said that it would fill the distribution channel blank by self-built or mergers and acquisitions, forming a regional operation center with local core companies, distributing network structure around the radiation area, and speeding up the rapid development of the national market. In addition, the company will enhance the upstream drug suppliers of bargaining power and control capabilities, thereby enhancing market competitiveness and profitability; third, increase investment in research and development.The company pointed out that the existing research and development investment and the international leading pharmaceutical companies still have a certain gap. The future company will vigorously promote the "from passive innovation to active innovation", "from technological innovation to the source of innovation extension" of the new Drug development strategy, further increase the raw materials and generic drug research and development investment; Four is the construction enterprise Information System. Through this platform, the scientific management of upstream suppliers and downstream sales terminal business data is beneficial to the company to achieve centralized procurement platform and marketing platform, enhance bargaining power; Five is to replenish liquidity and optimize financial structure.　　The company will let some of the funds to replenish liquidity, further optimize the company's capital structure. Shanghai Pharmaceutical Chairman Lu Mingfang said the fund-raising is mainly used for domestic and foreign pharmaceutical industry projects, mergers and acquisitions, pharmaceutical business network construction and mergers and acquisitions, and increase investment in research and development. "Through the a+h stock market, we truly become a dual-platform operation of the market-oriented, international companies, we are not for the capital operation, but hope that the funds for the development of pharmaceutical industry, to become the industry leader." "Analysts said the medicine felt a crisis" although there are more than 5 to raise investment, but the main aspect of the development of pharmaceutical circulation.　　"Yesterday, a Shanghai pharmaceutical industry researcher in the daily economic news interview, said that with the Chinese Medicine holdings in Hong Kong listed, Kyushu Tong is about to land A shares, Shanghai medical feel the pressure." According to his introduction, the Chinese medicine is the largest pharmaceutical business in the field of the eldest, Kyushu Pass ranked third, as the second Shanghai Medicine must act. Under the guidance of the Ministry of Commerce on the introduction of the policy to encourage the pharmaceutical business to become bigger and stronger, epitaxial development is the inevitable choice of large-scale business. Data show that, nationwide, Shanghai pharmaceutical industry is significantly inferior to the Chinese medicine holdings.　　In 2009, the Chinese medicine sales amounted to 44.6 billion yuan, while Shanghai pharmaceutical sales were about 30 billion yuan. It is noteworthy that after the integration of medicine, Shanghai Pharmaceutical has been pioneering the field of pharmaceutical business. In the first half of 2010, the group set up a wholly-owned distribution and retail platform, "Shanghai Pharmaceutical Distribution Holdings Limited" (Medicine Holdings), with the original medical shares as an integrated platform for comprehensive integration of pharmaceutical business. The first half of the company's pharmaceutical business (distribution and retail business) sales revenue of 14.32 billion yuan, an increase of 24.37%, compared with the 2009 16.8% growth significantly increased; Gross profit margin of 9.1%, compared with the same period last year, but slightly higher than the year 09, is still significantly higher than the domestic commercial gross margin 5%~8%　　Average level. Guo Shin Securities and pharmaceutical industry analyst Dingdan that the next 2 years, the cost of medicine in Shanghai there is room for decline. The first half of Guangzhou, the acquisition of the third largest distributor Zhongshan pharmaceutical, commercial areas of the national expansion of the initial step, with Jiangsu, Zhejiang, Fujian and other places to reach a number of regional distribution leading enterprises cooperation framework agreement. Mergers and acquisitions in the industrial sector are also expected to open.